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Influence networks based on coexpression
improve drug target discovery for the
development of novel cancer therapeutics
Nadia M Penrod1 and Jason H Moore2,3*
Abstract
Background: The demand for novel molecularly targeted drugs will continue to rise as we move forward toward the
goal of personalizing cancer treatment to the molecular signature of individual tumors. However, the identification of
targets and combinations of targets that can be safely and effectively modulated is one of the greatest challenges
facing the drug discovery process. A promising approach is to use biological networks to prioritize targets based on
their relative positions to one another, a property that affects their ability to maintain network integrity and propagate
information-flow. Here, we introduce influence networks and demonstrate how they can be used to generate
influence scores as a network-based metric to rank genes as potential drug targets.
Results: We use this approach to prioritize genes as drug target candidates in a set of ER+ breast tumor samples
collected during the course of neoadjuvant treatment with the aromatase inhibitor letrozole. We show that influential
genes, those with high influence scores, tend to be essential and include a higher proportion of essential genes than
those prioritized based on their position (i.e. hubs or bottlenecks) within the same network. Additionally, we show that
influential genes represent novel biologically relevant drug targets for the treatment of ER+ breast cancers. Moreover,
we demonstrate that gene influence differs between untreated tumors and residual tumors that have adapted to
drug treatment. In this way, influence scores capture the context-dependent functions of genes and present the
opportunity to design combination treatment strategies that take advantage of the tumor adaptation process.
Conclusions: Influence networks efficiently find essential genes as promising drug targets and combinations of
targets to inform the development of molecularly targeted drugs and their use.
Keywords: Breast cancer, Coexpression networks, Drug target discovery, Letrozole, Tumor adaptation
Background
As we continue the pursuit of personalized medicine in
cancer, where treatments are matched to the molecular
signature of individual tumors, the demand for new drugs
will continue to rise. Oncology drugs have historically
had high attrition rates in late-phase clinical trials due
to safety and toxicity concerns or a lack of efficacy [1,2].
The advent of molecularly targeted drugs has improved
attrition rates bringing more drugs to market [3], but the
efficacy of these drugs is often short-lived as tumors adapt
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to become resistant to their effects. To support the devel-
opment of novel drugs we need efficient ways to discover
better druggable targets to selectively kill cancerous cells
and better combinations of targets to prevent resistance.
Network biology is an attractive platform for the dis-
covery of novel drug targets because it captures both the
detail of individual molecular interactions and a global
snapshot of how these interactions fit together to create a
functional system. In this way, the network becomes amap
that can be used to strategically find points of interven-
tion, based on the context-dependent relationships of the
potential target, and that can be modulated to tweak the
biological function of the entire system. To identify tar-
gets for the treatment of cancer, the network can be used
to identify points of vulnerability that when targeted will
lead to the loss of viability.
© 2014 Penrod and Moore; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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Measures of node centrality, or how well a node is
embedded within the network, are one possible way
to identify such targets. Nodes that have many links,
called hubs, and those that lie in well-traveled paths,
called bottlenecks, are integral for maintaining network
integrity and paths of information-flow [4]. Genes or
gene-products that occupy these positions within a net-
work tend to be essential [4,5] which means they are
required for viability, and thus they become promising
drug targets for the treatment of cancer.
Here we introduce a network-based method for drug
target discovery called influence networks. Influence
networks convert weighted undirected networks into
weighted bidirectional networks where pairs of nodes are
connected by two links, one weighted to represent the
influence a given node has on its partner and the other
weighted to represent the influence the partner has on the
given node (Figure 1). From these networks we calculate
a cumulative influence score as a measure of the impor-
tance of each gene within the network. Using these scores
we rank the genes as potential drug targets from most
influential to least influential.
We apply this method to coexpression networks gener-
ated from transcriptional profiles of ER+ breast tumors
before, during, and after a course of neoadjuvant treat-
ment with the drug letrozole.We show that highly influen-
tial nodes tend to be essential, influential nodes are more
often essential than hubs or bottlenecks, and influential
genes make promising drug target candidates.
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Figure 1 Generating influence networks. Influence networks are
directed weighted networks (right) generated from undirected
weighted networks (left). Illustrated here is an example of a
coexpression network and its influence network. Influence is
calculated as the proportion of total edge weights a given node
shares with each of its neighboring nodes (see Methods). Here, red
links show the influence of node A on nodes B and C, which are
completely influenced by node A because they do not have other
neighbors to influence them. Blue links show the influence of nodes B
and C on node A. Node B has a greater influence on node A than
node C because the weight of the edge linking B to A is greater than
the weight of the edge linking C to A. The cumulative influence of
each node is calculated by summing the values of all outgoing edge
weights from a given node.
Methods
Gene expression data
Transcriptional profiles were generated from core biop-
sies extracted from ER+ breast tumors during the course
of neoadjuvant treatment with the aromatase inhibitor
letrozole [6,7]. Tumors were sampled before treatment
(n= 58), following 14 days (n= 58), and following 90
days (n= 60) on drug. Inclusion criteria required sam-
ples to contain at least 20% malignant tissue. RNA was
extracted from each sample, amplified, and hybridized to
Affymetrix HG-U133A GeneChip arrays. The data can be
accessed through the Gene Expression Omnibus (GEO)
database (GSE20181).
Gene expression data processing
The raw probe intensity (CEL) files were downloaded
fromGEO.We processed the data with a custom chip def-
inition file (CDF) to assign the most recent probe anno-
tations and to exclude promiscuous probes from further
analysis [8]. We used the R implementation of the robust
multi-array average (RMA) algorithm to background cor-
rect, normalize, and summarize the data [9].
Differential expression analysis
To select the subset of genes that are affected by letrozole
treatment we calculated differential expression between
genes in the tumor samples collected before treatment
and those collected following 90 days of treatment. Dif-
ferential expression analysis was done using the Linear
Models for Microarray Data (limma) method [10] imple-
mented in the limma package in R. This method models
the affect each treatment condition has on the expression
level of each gene. We chose this method because of its
demonstrated robust performance across a variety of sam-
ple sizes and noise levels [11]. We correct for multiple
hypothesis testing by setting a false discovery rate (FDR)
at 5% and genes below this value were considered dif-
ferentially expressed at a statistically significant level. We
used the set of differentially expressed genes to perform
coexpression analysis.
Coexpression networks
To generate sets of coexpressed gene pairs we calculate the
1st-order Spearman’s correlation coefficient [12] among
all pairs of differentially expressed genes. Spearman’s cor-
relation allows us to identify both linear and nonlinear
relationships and the 1st-order correlation, or partial cor-
relation, ensures we are only identifying direct gene-gene
relationships by removing associations that appear due
to common regulators. We generated three sets of coex-
pressed gene pairs: those that occur in the untreated
tumors, those that occur following 14 days of letrozole
treatment, and those that occur following 90 days of
letrozole treatment.
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Based on simulations carried out by de la Fuente et al.
[12], we chose a significance threshold of α = 0.01. We
validated this threshold through permutation testing
where the expression levels of each gene are randomized,
within each time point, across samples. From the ran-
domized data we calculated coexpression as described
and counted the number of gene-gene relationships
that meet our significance threshold. This process was
repeated 1000 times, and the counts were used to gener-
ate null distributions for each time-point. The observed
number of coexpression relationships, for each of the
three time-points, fall to the right, outside of the matched
null distribution.
We used the igraph package in R [13] to convert the lists
of pairwise coexpression relationships into undirected,
weighted coexpression networks where nodes represent
genes and edges connect pairs of genes that have a sta-
tistically significant partial correlation relationship. Edges
were weighted to reflect the partial correlation coefficient
shared between the pair of connected nodes. We gener-
ated three coexpression networks, one for the untreated
tumor samples, one for those that have been treated with
letrozole for 14 days, and one for those that have been
treated with letrozole for 90 days.
Influence networks
To generate influence networks from the weighted, undi-
rected coexpression networks we applied the methods
developed by Hangal et al. [14] (Figure 1) to get bidirec-
tional, weighted edges by calculating the influence each
node has on its neighbors as follows:
Influence(A,B) = pcor(B,A)∑
X pcor(B,X)
(1)
where Influence(A,B) is the influence of node A on node
B given the strength of node B’s partial correlation with
node A in proportion to the strength of node B’s partial
correlation with all other nodes denoted by X.
From the influence networks, we calculate a cumulative
influence score for each node as the sum of its influences
on all other nodes as follows:
Influence(A) =
∑
X
Influence(A,X) (2)
where Influence(A) is the influence score of node A.
Other network measures of influence
In general, nodes with high centrality scores tend to be
essential in complex networks, including those derived
from biological systems [4,5]. The two most often cited
measures of centrality are degree centrality and between-
ness centrality. Degree centrality is calculated by counting
the number of edges of a given node. Nodes with high
degree centrality are well-connected and referred to as
hubs. Betweenness centrality is calculated as the number
of shortest paths between all pairs of nodes that cross a
given node. Nodes with high betweenness centrality con-
trol the rate of information flow and are referred to as
bottlenecks.
Here we calculated the degree and betweenness cen-
tralities of the influence networks using the igraph pack-
age in R [13]. We calculated degree for outgoing edges
only because every edge is bidirectional. We calculated
betweenness with respect to the weighted and directed
edges.
Gene essentiality
To identify genes that are essential for breast cancer
cells to proliferation and survive in culture, we down-
loaded genome-wide pooled shRNA screen data across 29
breast cancer cell-lines from the COLT-Cancer database
[15]. Each cell-line was screened in triplicate and a Gene
Activity Ranking Profile (GARP) score, with an associ-
ated p-value, was developed by Marcotte et al. [16] to
reflect the essentiality of a given gene within a given cell-
line. Because tumors are heterogeneous and we do not
know which cell-lines best model the patient data used in
our analysis, we define essentiality as having a significant
GARP score (p ≤ 0.05) in at least one of the 29 breast
cancer cell-lines.
We calculated the proportion of influential genes in the
untreated tumors that are also essential. For comparisons
between measures of nodal importance, we calculated the
proportion of genes that are essential among genes rank-
ing in the top 25 for influence score, degree, or between-
ness centrality. We chose this number based on our prior
characterization of these networks where we classified
genes as hubs or bottlenecks if their degree or between-
ness centrality scores, respectively, were statistical outliers
[17]. For consistency, we choose the top influential genes
as those that are statistical outliers by their influence
scores. The numbers of genes comprising each of the cate-
gories across networks varies so we choose to compare the
greatest common number across categories which is 25.
Results
Influence networks
We first generated undirected weighted coexpression
networks from the set of genes that are differentially
expressed in ER+ breast tumor samples following neoad-
juvant treatment with the drug letrozole. We focus on the
set of differentially expressed genes to capture adaptation
to letrozole treatment at the expression level. To capture
dynamic coexpression changes throughout the course of
treatment, we generated three networks: one represent-
ing the untreated tumors, one representing early changes
following 14 days on letrozole, and one representing late
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changes following 90 days on letrozole. In these networks,
nodes represent genes and two genes are connected by an
edge if their expression levels are correlated by a statis-
tically significant 1st-order Spearman’s correlation coeffi-
cient. Edges were weighted by taking the absolute value of
the correlation coefficients that connect coexpressed pairs
of genes.
Coexpression networks based on correlation are undi-
rected because correlation is a symmetric measure of
dependence. In other words, when the expression levels
of two genes, A and B, are correlated the interpretation is
that the level of gene A depends on the level of gene B to an
equal extent that the level of gene B depends on the level of
gene A. However, we know that the relationships between
genes are actually asymmetric. For example, if gene A is a
transcription factor that regulates the expression of gene
B, the influence of A on B is usually greater than the influ-
ence of B on A. This distinction becomes critical when
identifying influential genes as potential drug targets.
To capture asymmetrical relationships between genes,
we converted our undirected weighted coexpression net-
works into directed weighted influence networks using a
method developed by Hangal et al. [14] (Figure 1). This
produces networks in which each correlated gene pair is
connected by two edges of opposite direction where one
edge reflects the influence of a given node on its part-
ner and the other edge reflects the amount a given node
is influenced by its partner. We sum the weights of the
outgoing edges for each node to calculate a cumulative
influence score for each gene.
Influence and essentiality
Influence is not a uniformly distributed property across
nodes. Most genes have limited influence. A few genes
are highly influential. The distributions of influence scores
consistently show this pattern at each of the three time-
points (Figure 2).
We hypothesized that highly influential genes will be
critical for maintaining the integrity of the network and
thus essential to the tumors. To test this, we calculated the
proportion of influential genes, selected as statistical out-
liers by influence score, in the untreated tumor network
that are identified as essential genes in an independent
shRNA screen of breast cancer cell-lines in the absence
of drug treatment [15]. We found that the set of influ-
ential genes are significantly enriched for essential genes
(p < .001, cumulative binomial distribution) (Figure 3).
We show this enrichment holds for a range of thresholds
(Additional file 1: Figure S1).
Influence and centrality
It has been shown that nodes that have high degree and/or
betweenness centralities are frequently associated with
essentiality [4,5]. To determine if the influencemetric pro-
vides different information than measures of centrality,
we compare the degree and betweenness for each gene
in the untreated tumor network with its corresponding
influence score.
We found that the degree of a gene and its influence
are highly correlated (r= 0.78, p < .001) (Figure 4) which
is consistent with the quantitative definition of influence.
However, the most influential genes are not consistently
found among those with the highest degree, so choos-
ing candidates based on a degree threshold would exclude
many genes of high influence.
The betweenness of a gene and its influence are also cor-
related (r= 0.61, p < .001) (Figure 5). Themost influential
genes tend to fall among those with high betweenness
scores but there is a lot of variability in influence at these
values of betweenness. Therefore, choosing candidates
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Figure 2 Influence score distributions. Distributions of influence scores within coexpression-based influence networks representing ER+ breast
tumors before, during, and after neoadjuvant letrozole treatment. These heavy-tailed distributions show that most genes have limited influence
while a few genes are highly influential. Boxplots show the spread of the influence scores including the median value and statistical outliers under
each treatment condition.
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Figure 3 Influential genes are enriched for essential genes. Influential genes, identified with the coexpression based influence network
representing untreated ER+ breast tumors, are enriched for essential genes in contrast to noninfluential genes within the same network (p < .001).
p-value calculated using the cumulative binomial distribution.
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Figure 4 Influence and degree centrality. The influence scores of genes within the coexpression based influence network of untreated ER+
breast tumors are correlated with their degree. Although influential nodes do not necessarily have high degree and nodes of high degree are not
necessarily influential. Labels correspond to the most influential genes presented in Table 1.
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Figure 5 Influence and betweenness centrality. The influence scores of genes within the coexpression based influence network of untreated
ER+ breast tumors are correlated with their betweenness centrality. Although influential nodes do not necessarily have high betweenness and
nodes of high betweenness are not necessarily influential. Labels correspond to the most influential genes presented in Table 1.
based on a betweenness threshold would include many
genes that have little influence.
We also calculated the proportion of essential genes
among those with the highest influence, degree, or
betweenness measures. We find a greater proportion of
essential genes among the influential nodes than among
hubs (p < .001, Fisher’s exact test) or bottlenecks
(p < .001, Fisher’s exact test). We show this trends is
maintained across a range of thresholds (Additional file 2:
Figure S2).
Influence to identify druggable targets
Having shown that influence identifies essential genes, we
selected the most influential genes within each network
for assessment as potential drug targets (Table 1). We are
looking for targets that will synergize with letrozole treat-
ment, and by using sequential biopsy samples during the
course of treatment, we have the unique opportunity to
identify targets in the untreated tumors and in the resid-
ual tumors after they have been rewired in an adaptive
response to 14 days and 90 days of drug treatment. Target-
ing these induced-essential genes additively with letrozole
as they become essential has the potential to stave off
resistance.
We compare the influence scores among the most influ-
ential genes under each treatment condition with their
corresponding scores at the two other treatment condi-
tions (Figure 6). As expected, in all cases, the influence
scores among the top genes at a given time-point are sta-
tistically significantly higher than their influence scores at
the other time-points (p < .001, Student’s t-test). We also
show that changes in influence scores among the genes
within these sets are larger than would be expected by
random chance (Additional file 3: Figure S3).
The genes with the highest influence are the transmem-
brane protein TMEM14A in the untreated tumor sam-
ples, the zinc-finger transcription factor ZFHX4 following
14 days of letrozole treatment, and the redox protein
CYB5R3 following 90 days of letrozole treatment. Each
of these genes have been associated with cancer although
their functional roles are still under investigation making
them novel potential targets.
TMEM14A has been shown to play a functional role
in the suppression of apoptosis by inhibiting the pro-
apoptotic protein Bax and by regulating mitochondrial
membrane potential [18]. TMEM14A may also play a
role in the regulation of planar cell polarity by trafficking
planar cell polarity proteins to the membrane including
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Table 1 Most influential genes
Untreated 14 Days Letrozole 90 Days Letrozole
Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol
1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3
2 1843 DUSP1 4701 NDUFA7 7083 TK1
3 51022 GLRX2 715 C1R 1292 COL6A2
4 1434 CSE1L 79818 ZNF552 857 CAV1
5 8522 GAS7 4046 LSP1 5437 POLR2H
6 51668 HSPB11 1727 CYB5R3 9833 MELK
7 10456 HAX1 357 SHROOM2 54861 SNRK
8 9902 MRC2 283298 OLFML1 4830 NME1
9 4706 NDUFAB1 23179 RGL1 231 AKR1B1
10 23560 GTPBP4 1809 DPYSL3 10418 SPON1
11 79633 FAT4 857 CAV1 2350 FOLR2
12 10418 SPON1 274 BIN1 10979 FERMT2
13 471 ATIC 79833 GEMIN6 11096 ADAMTS5
14 6403 SELP 11222 MRPL3 4638 MYLK
15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4
16 23452 ANGPTL2 6241 RRM2 54922 RASIP1
17 54861 SNRK 1289 COL5A1 6934 TCF7L2
18 2034 EPAS1 8434 RECK 4072 EPCAM
19 30008 EFEMP2 429 ASCL1 4701 NDUFA7
20 25999 CLIP3 3426 CFI 404672 GTF2H5
21 4311 MME 332 BIRC5 6241 RRM2
22 4747 NEFL 2 A2M 2192 FBLN1
23 1809 DPYSL3 10730 YME1L1 25959 KANK2
24 28998 MRPL13 11130 ZWINT 55651 NHP2
25 25959 KANK2 1292 COL6A2 5050 PAFAH1B3
Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER+ breast tumors before, during, and after a course of
neoadjuvant treatment with the drug letrozole. Bold font indicates genes that are also classified as hub-bottleneck genes.
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Figure 6 Influence scores among top candidates across networks. The influence scores of the most influential genes (Table 1) within a time
point are shown across each of the three treatment conditions illustrating that influence is a condition-dependent property. For each comparison,
the influence scores among the top genes at a given time-point are statistically significantly higher than their influence scores at the other
time-points (p < .001, Student’s t-test).
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VANGL2 [19], a protein that promotes migration and
invasion in human cancer cells [20].
ZFHX4 is a gene of unknown function. In beef cat-
tle it has been associated with the regulation of puberty
through predicted participation in protein-protein inter-
actions with androgen receptor (AR) and peroxisome
proliferator-activated receptor gamma (PPARG) [21].
Additionally, a role for ZFHX4 in neuronal and muscle
differentiation in mice has been suggested [22].
The CYB5R3 gene balances the NAD+/NADH ratio
within cells to maintain redox homeostasis. CYB5R3 has
been associated with mitochondrial dysfunction in cancer
[23], a process that has been shown to play a context-
dependent role in the promotion of tumor growth [24].
Notably, in addition to the discovery of novel drug tar-
gets we also identify established targets by querying Drug-
Bank [25]. Twelve of the most influential genes across
the three time-points are targeted by FDA approved
drugs including five oxidoreductases (GLRX2, CYB5R3,
NDUFA7, AKR1B1, RRM2), two proteases (SELP, MME),
a methyltransferase (ATIC), a membrane transporter
(FOLR2), a carrier protein (NDUFAB1), a cytokine (A2M),
and a complement component (C1R). Additionally, five of
the most influential genes following 90 days of letrozole
treatment are the targets of experimental compounds.
These genes include two kinases (TK1, NME1), a protease
(ADAMTS5), a receptor (EPCAM), and an acetylhydro-
lase (PAFAH1B3). The availability of drugs provides an
opportunity to expedite biological validation of these tar-
gets with the potential to repurpose some of these drugs
for the treatment of breast cancer.
Discussion
Network biology provides a map of the molecular inter-
actions that underlie biological function making it an
intuitive and promising approach for the identification of
potential drug targets based on their context-dependent
relationships. Here we introduce influence networks as a
novel approach to the identification of the most impor-
tant or influential nodes within these networks as poten-
tial drug targets for cancer therapeutics. We apply this
method to three coexpression networks generated from
biopsies of ER+ breast tumors during the course of neoad-
juvant treatment with the drug letrozole to identify novel
targets for the rational design of combination treatment
strategies.
We have shown that few nodes are highly influen-
tial suggesting that nodes are more likely to be influ-
enced than to be influential. Additionally, influence is
a transitory nodal property changing as the network is
rewired by letrozole treatment. In this way, the influence
score reflects the context-dependent functions of genes.
These results are consistent with a study of gene regu-
latory networks showing that nodes holding important
positions within the network are transient as the inter-
actions between transcription factors and target genes
change in a condition dependent manner [26].
Measures of centrality are routinely used to determine
the importance of nodes within biological networks [4].
One would expect degree centrality and influence to be
correlated because the influence score is calculated as the
sum of edge weights, so nodes of high degree will tend
to have high influence. A correlation between influence
and betweenness centrality is not as obvious but it can
be explained by data showing that degree and between-
ness are correlated [5]. However, these relationships are
not absolute as hubs and bottlenecks are not necessarily
highly influential and vice versa.
A study evaluating hubs and bottlenecks in protein
networks concluded that degree is a better predictor
of essentiality in undirected interaction networks while
betweenness is a better predictor of essentiality in directed
regulatory networks [5]. Influence networks convert undi-
rected networks into directed networks where influence
scores are a better predictor of essentiality than either
degree or betweenness. The advantage of influence is that
it incorporates information about second neighbors when
determining the influence a given gene has on its partner.
This captures asymmetric relationships between genes
providing a better informed prediction of overall influence
within the network.
A recent study to catalog knockout phenotypes in mice
at the genome-wide level revealed that although there is a
literature bias toward known genes [27], unknown genes
are equally likely to underlie disease and to be essential
[28]. Here we have identified three relatively unknown
genes, TMEM14A, ZFHX4, and CYB5R3, as the most
influential genes and thus the top candidates as poten-
tial drug targets across our networks. These targets are
biologically relevant playing roles in cancer associated
pathways including resisting apoptosis, invasion, differen-
tiation and deregulating cellular energetics [29].
The full potential of molecularly targeted drugs lies
in combination therapy. There are at least two ways
to think about drug combinations for the treatment of
cancer. One is synthetic lethality where redundant func-
tions must be targeted together to cause cell death [30].
The other is induced-essential synthetic lethality where
compensatory functions must be targeted together to
cause cell death [30]. The distinction is that the com-
pensatory functions are not activated until the cell has
been rewired by a genetic mutation or environmental
perturbation such as drug treatment. Here we incorpo-
rate the concept of induced-essentiality into drug target
discovery by identifying targets that become influential
only after the tumors have undergone 14 days or 90 days
of letrozole treatment. This presents an opportunity to
design combination therapies that sequentially add drugs
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to letrozole treatment as the tumors adapt. In this partic-
ular case, neoadjuvant letrozole is given for 90 days but
recent trials have shown that patient tumors continue to
respond to the drug for up to one year [31-34] suggest-
ing that in this setting, sequential therapy is a practical
strategy.
Conclusion
As the molecular characterization of tumors has become
routine, molecularly targeted drugs have become a main-
stay for the treatment of cancer. The success of a targeted
therapeutic depends not only on the identification of
the most appropriate target but also on how it is com-
bined with other targeted drugs. Here we have introduced
influence networks as a method to prioritize genes as
potential drugs targets. We have shown that as tumors
adapt to treatment with the drug letrozole, these poten-
tial targets change, reflecting changes in the underlying
function of genes in the presence of the drug. The results
of our analysis have implications in the design of com-
bination therapy treatment strategies that are applicable
beyond letrozole and ER+ breast cancer. In general, tar-
geting influential genes as they become essential for tumor
viability throughout the adaptation process presents an
opportunity to enhance the effects of molecularly targeted
drugs by staying a step ahead of resistance. Network-based
metrics are an effective way to identify targets and their
combinations based on the context-dependent roles they
play within the system.
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